BackCo-Diagnostics Overview

Co-Diagnostics EBIT

Co-Diagnostics's EBIT is $-46M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$6.31M
↑ 10.6% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$46.45M
↓ 34.49% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Co-Diagnostics (CODX) FAQ

The latest EBIT for CODX is $-46M as of September 2026. That compares with $-35M in the prior-year period — down 34.5% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Co-Diagnostics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CODX's EBIT moved from $-35M to $-46M — a 34.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Co-Diagnostics's operating scale or balance-sheet position.

Against Healthcare companies, CODX currently prints $-46M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Co-Diagnostics's growth, margins, and balance sheet.

A EBIT figure of $-46M for CODX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting CODX's EBIT ($-46M), review year-over-year change from $-35M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.